Covid-19 Vaccine Novavax Expects the US to Approve It From May

Covid-19 vaccine Novavax expects the US to approve it from May: Novavax CEO Stanley Erck has predicted that the company’s coronavirus vaccine could be licensed in the United States as early as May. Trial results have shown the vaccine to be highly effective, although not as effective against the variant first found in South Africa, Business Insider reports. In Spain, according to the latest official communications, it could be authorized in April, as announced by the Minister of Health, Carolina Darias.

“The American biotech company has agreed to supply 110 million doses to the United States,” Erck told CNBC., Adding that he expected them to be delivered in June or July. But he has cautioned that this depended on the US FDA issuing an emergency use authorization for the vaccine, based largely on data from trials conducted in the UK.

Novavax is conducting 3 efficacy trials at the same time: in the UK, South Africa and the USA. Data from the third phase of the trial in the United States, which has 30,000 participants, will not be released for “probably a couple of months,” he warns.

Look This: peryourhealth.com pay bill

However, Novavax already has data from the third phase of the vaccine efficacy trial in the UK, suggesting that the vaccine has an average efficacy of 89.3 percent in protecting against coronavirus.

Europe targets April to approve Novavax vaccine

Although, a few days ago, the Minister of Health, Carolina Darias, explained that this vaccine, which could be the fifth approved in Spain, could be authorized as of April. He pointed this out during his visit to the Biofabri plant in O Porrino, Pontevedra, belonging to the Zendal biopharmaceutical group.

Precisely, this company is in charge of the production of this vaccine against the coronavirus, being the first biopharmaceutical in Spain that fully manufactures a vaccine against Covid-19. The minister’s words came after the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) began its review at the beginning of this February. See this peryourhealth portal for getting more updates on health.